Adoptive immunotherapy for primary lung cancer.
The data presented in the present clinical trial demonstrated that adoptive immunotherapy using IVS cells and alpha CD3-AT cells for primary lung cancer patients may have therapeutic efficacy in selected groups of patients. Further investigation, such as induction of cytokine genes into effector cells to maximize the in vivo anti-tumor activity, combination of active immunization (tumor vaccine) and adoptive immunotherapy (10) would be definitely required for utilization of adoptive immunotherapy for lung cancer.